|
Corporate News
26-Dec-22
|
|
|
|
|
|
|
Alembic receives USFDA approval for Fulvestrant Injection
|
|
|
|
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per SingleDose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor
antagonist indicated for the treatment of breast cancer.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending Sep 2022 according to IQVIA.
|
|
Previous News |
Stock Alert: Alembic Pharma, Bajel Projects, Zydus Lifesciences, Lupin, Adani Enterprises, Biocon
(
Market Commentary
-
Stock Alert
30-Sep-24
08:34
)
|
|
Intellect Design Arena Ltd leads losers in 'A' group
(
Hot Pursuit
-
10-May-24
15:00
)
|
|
Alembic Pharmaceuticals consolidated net profit rises 48.01% in the December 2023 quarter
(
Results
-
Announcements
05-Feb-24
14:52
)
|
|
Alembic Pharma gets USFDA nod for stroke and blood clots drug
(
Hot Pursuit
-
18-Jun-24
14:27
)
|
|
Alembic Pharmaceuticals receives USFDA approval for Betamethasone Valerate Foam
(
Corporate News
-
24-Aug-24
14:03
)
|
|
Alembic Pharmaceuticals receives USFDA approval for Dabigatran Etexilate Capsules
(
Corporate News
-
18-Jun-24
18:52
)
|
|
Alembic Pharma’s Gujarat unit gets EIR from USFDA
(
Hot Pursuit
-
28-Sep-24
13:02
)
|
|
Alembic Pharma gets USFDA nod for Paliperidone extended-release Tablets
(
Hot Pursuit
-
27-Sep-24
13:40
)
|
|
Alembic Pharma gets USFDA final approval for Prazosin Hydrochloride capsules
(
Hot Pursuit
-
08-Mar-23
09:19
)
|
|
Volumes spurt at Alembic Pharmaceuticals Ltd counter
(
Hot Pursuit
-
24-Apr-23
14:30
)
|
|
Volumes soar at Alembic Pharmaceuticals Ltd counter
(
Hot Pursuit
-
02-Jan-24
14:30
)
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|